Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05060315 · ClinicalTrials.gov registry record
Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin
A clinical trial, sponsored by United Therapeutics.
- Terminated
- Registry status
- 9
- Enrollment target
NCT05060315: Clinical Trial study, sponsored by United Therapeutics.
NCT05060315 is a clinical trial that was terminated before completion, run by United Therapeutics. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05060315 was terminated before completion, sponsored by United Therapeutics.
- TERMINATED
- Registry status
- 9 participants
- Enrollment target
Study Summary
To observe and assess drug administration activities, time spent on drug administration activities, and patient-reported outcomes (PROs) including quality of life, treatment satisfaction, and patient perception of devices related to use of United Therapeutics Corporation (UTC)-developed next-generation infusion pumps to administer Remodulin in patients with Pulmonary Arterial Hypertension (PAH).
Primary Outcome
Participants will be asked to participate in a comprehensive collection of the drug administration activities data consisting of a 7-day evaluation period of daily drug administration activities pertaining to their next generation infusion pump via the Drug Administration Activities Diary.
Interventions
- COMBINATION_PRODUCT Remunity Pump for Remodulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-07-05 |
| Est. Completion | 2024-12-31 |
Why NCT05060315 stopped before completion
NCT05060315 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Remunity Pump for Remodulin is the first listed.
NCT05060315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05060315 about?
NCT05060315 is a clinical study titled "Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin". To observe and assess drug administration activities, time spent on drug administration activities, and patient-reported outcomes (PROs) including quality of life, treatment satisfaction, and patient perception of devices related to use of United Therapeutics Corporation (UTC)-developed next-generat...
What is the current status of trial NCT05060315?
This trial is currently terminated. The enrollment target is 9 participants. The study started on 2023-07-05. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT05060315?
The interventions under investigation include: Remunity Pump for Remodulin (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05060315?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI